Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04802395 · ClinicalTrials.gov registry record

Real World Evidence Clinical Utility Study of KidneyIntelX

A clinical trial of Chronic Kidney Diseases and Diabetic Kidney Disease, sponsored by Renalytix AI.

Recruiting
Registry status
10,000
Enrollment target
1
Study location

NCT04802395 is a study of Chronic Kidney Diseases and Diabetic Kidney Disease that is actively recruiting participants, run by Renalytix AI. The registered enrollment target is 10,000 participants, above the 308-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (3147% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04802395, a study of Chronic Kidney Diseases and Diabetic Kidney Disease, is actively recruiting participants, sponsored by Renalytix AI.

RECRUITING
Registry status
10,000 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.

Interventions

  • DIAGNOSTIC_TEST KidneyIntelX

Study Locations (1)

New York

  • Mount Sinai Health System - New York

Trial Details

FieldValue
Enrollment Target 10,000 participants
Start Date 2021-03-02
Est. Completion 2026-12-01

Sponsor

Renalytix AI

4 total trials

What the Registry Record Tells You About NCT04802395

The ClinicalTrials.gov registry entry for NCT04802395 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 308-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (3147% higher). The listed sponsor is Renalytix AI, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 1 intervention - of which KidneyIntelX is the first listed.

NCT04802395 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT04802395 about?

NCT04802395 is a clinical study titled "Real World Evidence Clinical Utility Study of KidneyIntelX". The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.

What is the current status of trial NCT04802395?

This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2021-03-02. Estimated completion is 2026-12-01.

What conditions does trial NCT04802395 study?

This clinical trial studies the following conditions: Chronic Kidney Diseases, Diabetic Kidney Disease.

What interventions are being tested in trial NCT04802395?

The interventions under investigation include: KidneyIntelX (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04802395?

This trial is sponsored by Renalytix AI, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04802395 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Kidney Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.